Literature DB >> 10562709

Immune evasion of tumor cells using membrane-bound complement regulatory proteins.

A Gorter1, S Meri.   

Abstract

Membrane-bound complement regulatory proteins (mCRPs) play an important role in the protection of cells from complement-mediated injury. It is now apparent that malignant tumor cells also express these proteins to escape complement attack. Here, Arko Gorter and Seppo Meri discuss the implications of complement resistance for the immunotherapeutic treatment of solid tumors with monoclonal antibodies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10562709     DOI: 10.1016/s0167-5699(99)01537-6

Source DB:  PubMed          Journal:  Immunol Today        ISSN: 0167-5699


  54 in total

1.  Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack.

Authors:  Marc Cinci; Srinivas Mamidi; Wenhan Li; Volker Fehring; Michael Kirschfink
Journal:  Target Oncol       Date:  2014-11-15       Impact factor: 4.493

2.  CD55 expression patterns on intestinal neuronal tissue are divergent from the brain.

Authors:  K A Gelderman; H J M A A Zijlmans; M J Vonk; A Gorter
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

Review 3.  Protein engineering to target complement evasion in cancer.

Authors:  Darrick Carter; André Lieber
Journal:  FEBS Lett       Date:  2013-11-14       Impact factor: 4.124

4.  FHR4-based immunoconjugates direct complement-dependent cytotoxicity and phagocytosis towards HER2-positive cancer cells.

Authors:  Carole Seguin-Devaux; Jean-Marc Plesseria; Charlène Verschueren; Cécile Masquelier; Gilles Iserentant; Marie Fullana; Mihály Józsi; Jacques H M Cohen; Xavier Dervillez
Journal:  Mol Oncol       Date:  2019-09-30       Impact factor: 6.603

Review 5.  Complement System: a Neglected Pathway in Immunotherapy.

Authors:  Anne Bordron; Cristina Bagacean; Adrian Tempescul; Christian Berthou; Eléonore Bettacchioli; Sophie Hillion; Yves Renaudineau
Journal:  Clin Rev Allergy Immunol       Date:  2020-04       Impact factor: 8.667

6.  Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection.

Authors:  Juan Carlos Varela; Carl Atkinson; Robert Woolson; Thomas E Keane; Stephen Tomlinson
Journal:  Int J Cancer       Date:  2008-09-15       Impact factor: 7.396

Review 7.  Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer.

Authors:  Sonia I Vlaicu; Cosmin A Tegla; Cornelia D Cudrici; Jacob Danoff; Hassan Madani; Adam Sugarman; Florin Niculescu; Petru A Mircea; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

8.  Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.

Authors:  A Michlmayr; T Bachleitner-Hofmann; S Baumann; M Marchetti-Deschmann; I Rech-Weichselbraun; C Burghuber; U Pluschnig; R Bartsch; A Graf; R Greil; G Allmaier; G Steger; M Gnant; M Bergmann; R Oehler
Journal:  Br J Cancer       Date:  2010-09-28       Impact factor: 7.640

9.  Growth delay of human bladder cancer cells by Prostate Stem Cell Antigen downregulation is associated with activation of immune signaling pathways.

Authors:  Emanuele Marra; Paolo Uva; Valentina Viti; Valeria Simonelli; Eugenia Dogliotti; Emanuele De Rinaldis; Armin Lahm; Nicola La Monica; Alfredo Nicosia; Gennaro Ciliberto; Fabio Palombo
Journal:  BMC Cancer       Date:  2010-04-07       Impact factor: 4.430

10.  Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells.

Authors:  K E Odening; W Li; R Rutz; S Laufs; S Fruehauf; Z Fishelson; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.